Cultivation agreement with Cannprisma, Portugal

26
th
March 2024
FOR PUBLIC RELEASE
Rua Bioscience partners with Cannprisma for pre-commercial cannabis trials in Portugal
TairawhiƟ, New Zealand – Rua Bioscience today announced another milestone in its strategy to
commercialise its proprietary geneƟcs globally. The TairawhiƟ-headquartered company has signed an
agreement with Portugal-based Cannprisma to conduct pre-commercial trials of Rua’s unique
cannabis varieƟes.
Following this agreement, Rua will send cannabis clones to Portugal - the first clones to be legally
exported from New Zealand.
The agreement is laid out in two stages: the crucial first stage is pre-commercial culƟvaƟon trials in
Portugal to prove the performance of the varieƟes in the new environment. Following successful
trials, the agreement allows for commercial producƟon.
“This partnership underscores Rua’s commitment to our strategy of culƟvaƟng our geneƟcs at scale
in export markets,” said Rua CEO Paul Naske.
“Portugal is an efficient and well-established culƟvaƟon and manufacturing hub for cannabis
products. Cannprisma have a proven track record in the development, culƟvaƟon and export of high-
quality medicinal cannabis.”
“By conducƟng trials in collaboraƟon with Cannprisma, we anƟcipate generaƟng important data to
scale our unique geneƟcs for commercial producƟon for sales in the key markets of Germany and the
UK.”
Rua began selling products in Germany in May 2023, in collaboraƟon with distribuƟon partner
Nimbus Health. In December, Rua signed a distribuƟon agreement with Target Health to supply Rua
product in the growing UK market.
www.ruabio.com
www.cannprisma.com
ENDS
The person who authorised this announcement:
Paul Naske
Chief ExecuƟve Officer
Paul.naske@ruabio.com
+64 21 445154

For media inquiries, please contact: Paul Naske - paul.naske@ruabio.com